This study looks at how acalabrutinib and obinutuzumab work on untreated follicular lymphoma or other similar non-Hodgkin lymphomas. Follicular lymphoma is a type of cancer that affects the lymph nodes. Acalabrutinib is a drug that may stop cancer cells from growing by blocking certain enzymes. Obinutuzumab is a type of immunotherapy that may help the body's immune system attack cancer cells.

• The study lasts up to 12 months, with treatments every 28 days.
• Participants must visit the clinic regularly for treatment and follow-up checks.
• There might be risks, like side effects from the medicines, but doctors will monitor closely.

To join, you must be at least 18 years old and have not received treatment for your lymphoma. You should not have any other serious health conditions. If you're a woman who can have children, you need to use birth control during the study. If you think you might be a good fit, talk to your doctor about joining this study to see if it's right for you.